Cleantech acquires rights to Bolivian gold-antimony project from Silver Elephant
Located near the capital city of La Paz, the project covers an area of approximately 256 hectares (ha).
On 8 April 2025, the two companies entered into an agreement allowing CleanTech to take over Silver Elephant's rights to purchase 100% equity interests in Mururata, which owns the mining rights to the Triunfo Project.
Oracle Commodity Holding, a major shareholder in CleanTech, is also significantly owned by Silver Elephant, establishing a related-party relationship between the companies under Multilateral Instrument 61-101.
The transaction's value does not exceed 25% of CleanTech's market capitalisation, which was approximately C$6.45m as of 5 August 2025, allowing CleanTech to utilise exemptions from formal valuation and minority approval requirements.
Silver Elephant's exploration efforts at El Triunfo have yielded positive results, with the initial drilling in 2020 uncovering 49m at 0.42 grams per tonne (g/t) of gold, 35g/t silver, 1.2% zinc and 0.8% lead.
The mineralisation at El Triunfo is hosted in meta-sediments dating back to the Silurian and Devonian periods. These meta-sediments have been intruded by plutonic batholiths, which are believed to be related to the mineralising events.
This type of mineralisation is not uncommon in Bolivia, with similar occurrences found at Cerro Rico and Porco.
The maiden drill programme conducted by Silver Elephant has confirmed the mineralisation's broad continuity, spanning at least 225m in strike and remaining open beyond 100m depth in both east and west directions.
The mineralisation is primarily found in altered black shales, featuring hydrothermal sheeted quartz-carbonate vein sets concentrated along regional anticlinal fold structures.
"Cleantech acquires rights to Bolivian gold-antimony project from Silver Elephant " was originally created and published by Mining Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
登入存取你的投資組合
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT
By GlobeNewswire Published on August 16, 2025, 02:30 IST LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN LEADING EDGE MATERIALS IN ANY JURISDICTION. Vancouver, August 15, 2025 – Leading Edge Materials Corp. ('Leading Edge Materials' or the 'Company') (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces announce the closing of the non-brokered private placement financing (the 'Private Placement') previously announced on June 10, 2025. Pursuant to the Private Placement, the Company has issued 17,738,500 units (the 'Units') at a price of C$0.16 per Unit for aggregate gross proceeds of C$2,838,160. Each Unit consists of one (1) common share (each, a 'Common Share') in the capital of the Company and one (1) Common Share purchase warrant (a 'Warrant'). Each Warrant will entitle the holder to purchase one Common Share (a 'Warrant Share') at a price of C$0.32 per Warrant Share until the date which is four (4) years from the closing date of the Private Placement (the 'Closing Date'). Leading Edge Materials intends to use net proceeds for the Company's projects, located in Sweden and Romania and for general working capital and corporate purposes. A finder's fee of 6% was paid to arm's length third party on a portion of the Private Placement. The Private Placement is subject to final approval from the TSX Venture Exchange (the 'Exchange'). The securities issued pursuant to the Private Placement are subject to applicable statutory resale restrictions, including a hold period expiring on December 15, 2025, pursuant to applicable Canadian securities laws. Insiders of the Company purchased a total of 10,666,000 Units under the Private Placement which constitutes a 'related party transaction' as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 based on the fact that neither the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company's market capitalization as determined in accordance with MI 61-101. Mr. Eric Krafft, a director of the Company, has subscribed for and acquired 10,666,000 Common Shares under the Private Placement. Prior to the Private Placement, Mr. Krafft beneficially owned and controlled 85,056,577 Common Shares and 22,852,173 warrants of the Company. Mr. Krafft is a Control Person (as defined by the policies of the Exchange), beneficially holding 95,722,577 common shares and 33,518,173 warrants of the Company, representing approximately 38.30% of the issued and outstanding Common Shares on a non-diluted basis, and 48.28% on a partially diluted basis, assuming the exercise of warrants held by Mr. Krafft only. The Company obtained disinterested shareholder approval at the Annual General Meeting held on July 24, 2020 for Mr. Krafft to become a Control Person of the Company. Eric Krafft has acquired the Units for investment purposes and has a long-term view of his investment. In the future, Mr. Krafft may take such actions in respect of his investment in the Company as he may deem appropriate, depending on the market conditions and circumstances at that time. The foregoing disclosure regarding Mr. Krafft's holdings is being disseminated pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (NI 62-103). A copy of Mr. Krafft's early warning report will appear on the Company's profile on SEDAR Plus. The information herein with respect to the number of Mr. Krafft's securities and his intention relating thereto are not within the knowledge of the Company and are provided by Mr. Krafft. The securities have not been, and will not be, registered under the U.S. Securities Act, or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is not a prospectus under Regulation (EU) 2017/1129 (the 'EU Prospectus Regulation'). The Company has not authorized any offer of securities to the public (as defined in the EU Prospectus Regulation) in any EEA member state and no such prospectus has been or will be prepared in connection with the Private Placement. On behalf of the Board of Directors, Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at: [email protected] Follow usTwitter: Linkedin: About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden) and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information This information is information that Leading Edge Materials Corp. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at August 15, 2025 at 2:30 PM Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol 'LEM', OTCQB under the symbol 'LEMIF' and Nasdaq First North Stockholm under the symbol 'LEMSE'. Svensk Kapitalmarknadsgranskning ('SKMG') is the Company's Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email [email protected] or by phone +46 (0)8 913 008. Reader Advisory This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including statements with respect to the closing of the Private Placement, the receipt of regulatory approvals, and the use of proceeds from the Private Placement. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, the Company's ability to close the Private Placement, the Company's ability to obtain the required regulatory approvals, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Important information for EEA Investors The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. Any investment decision in connection with the Private Placement must be made on the basis of all publicly available information relating to the Company and the Company's shares/Units. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares/Units. This press release is not a prospectus for the purposes of the EU Prospectus Regulation. Leading Edge Materials has not authorized any offer to the public of Units, shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, 'qualified investors' who are (i) persons having professional experience in matters relating to investments who fall within the definition of 'investment professionals' in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Attachment LEM – 2025 News Release Annoucing Closing of Financing-final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
10 hours ago
- Yahoo
CleanTech Announces Grant of Stock Options
Vancouver, British Columbia--(Newsfile Corp. - August 15, 2025) - CleanTech Vanadium Mining Corp. (TSXV: CTV) (OTCQB: CTVFF) (FSE: C9R) ("CleanTech" or the "Company") announces that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors, officers, employees and consultants to acquire a total of 875,000 common shares in the capital of the Company at an exercise price of $0.06. All Options were granted pursuant to the Company's 10% rolling stock option plan (the "Plan") and are subject to the terms of the Plan, the applicable grant agreements and the requirements of the TSX-V. The Options are exercisable for a five-year term expiring August 14, 2030. The Options will vest at 12.5% per quarter for the first two years following the grant date. About CleanTech Vanadium Mining Corp. CleanTech is a mining company focused on critical mineral resources in the USA. The Company has an option to acquire 7,180 acres of mineral rights with historic Fluorspar resources across multiple projects in Illinois-Kentucky Fluorspar district. CleanTech also owns a 100% interest in the Gibellini Vanadium Mine Project in Nevada. Further information on CleanTech can be found at ON BEHALF OF THE BOARD "John Lee" Chief Executive Officer For more information about CleanTech, please contact: Phone: 1.877.664.2535Email: info@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. ('Tvardi') (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic pulmonary fibrosis (IPF); topline data on track for Q4 2025. Submitted an Investigational New Drug (IND) application for its second clinical candidate, TTI-109, with the U.S. Food and Drug Administration (FDA) in June 2025. Announced that an abstract, entitled Single Cell Transcriptomics in A Treatment Status Segregated Cohort Exposes a STAT-3-Regulated Therapeutic Gap in Idiopathic Pulmonary Fibrosis, was presented at the American Thoracic Society (ATS) 2025 Annual Conference. Completed its merger with Cara Therapeutics, transitioning Tvardi into a publicly traded company. Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, 'We are on track for topline data in the fourth quarter from our fully enrolled REVERT IPF Phase 2 clinical trial. These data will offer important additional insights into the safety and efficacy of TTI-101, and, if positive, we believe will further validate our approach of targeting STAT3, a central mediator of fibrosis, to treat patients with IPF. 'In parallel, our Phase 2 REVERT Liver Cancer trial continues to enroll patients, and we remain on track to report topline results in the first half of 2026. Prior interim data from this ongoing study demonstrated clinically meaningful activity of TTI-101 as both monotherapy and in combination with established anti-cancer agents across treatment lines. 'Importantly, we are well-financed through these potential value inflection points, and into Q4 of next year. We believe we are very well positioned to bring meaningful innovation to patients living with fibrosis driven-diseases while creating significant value for our company.' Upcoming Milestones: Data from the company's ongoing REVERT IPF Phase 2 clinical trial of TTI-101 anticipated in 4Q 2025 Preliminary topline data from the company's ongoing REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 anticipated in 1H 2026 Second Quarter 2025 Financial Results Research and development expenses for the three months ended June 30, 2025, were $5.8 million as compared to $6.5 million for the comparable period in 2024. The decrease of $0.7 million was primarily driven by clinical, pre-clinical, and CMC costs associated with TTI-101. General and administrative expenses for the three months ended June 30, 2025, were $3.1 million as compared to $650,000 for the comparable period in 2024. The increase of $2.4 million was primarily driven by increases in professional fees of $1.6 million, attributable to increased legal, accounting and audit fees incurred as a result of the merger. The remaining increase was attributable to increases in personnel costs, insurance costs, and other costs. Net income for the three months ended June 30, 2025, was $4.2 million as compared to a net loss of $7.0 million for the comparable period in 2024. The improvement in net income was due primarily to a $12.8 million remeasurement gain on Tvardi's Convertible Notes recognized in the second quarter of 2025. Basic and diluted net income (loss) per share attributable to common shareholders for the three months ended June 30, 2025, were a net gain of $0.51 and net loss of $1.00, respectively, compared to a net loss of $2.71 on a basic and diluted basis for the comparable period in 2024. Cash, cash equivalents and short-term investments as of June 30, 2025, were $41.0 million, as compared to $31.6 million as of December 31, 2024. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). To learn more, please visit or follow us on LinkedIn and X (Twitter). Cautionary Statement Regarding Forward-looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi's product candidates; its ongoing clinical trials; its anticipated cash runway; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials; the significant net losses Tvardi has incurred since inception; Tvardi's ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi's clinical trials; the outcome of preclinical testing and clinical trials of the Tvardi's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi's product candidates; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; Tvardi's anticipated cash runway; Tvardi's ability to attract, hire, and retain skilled executive officers and employees; Tvardi's ability to protect its intellectual property and proprietary technologies; Tvardi's reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi's filings with the Securities and Exchange Commission, including the 'Risk Factors' section of the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and Tvardi's other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC's website at All forward-looking statements contained in this press release speak only as of the date on which they were made. The combined company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. (Unaudited) As of December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 20,648 $ 31,614 Short-term investments 20,346 — Prepaid expenses and other current assets 2,136 72 Total current assets 43,130 31,686 Property and equipment, net 68 84 Intangible assets, net 354 385 Operating lease right-of-use assets 181 216 Deferred offering costs — 2,811 Other non-current assets 17 17 Total assets $ 43,750 $ 35,199 Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 2,425 2,186 Accrued expenses 8,144 8,078 Operating lease liabilities, current portion 109 103 Total current liabilities 10,678 10,367 Operating lease liabilities, net of current portion 145 201 Convertible Notes — 30,259 Total liabilities 10,823 40,827 Commitments and contingencies (Note 13) Redeemable convertible preferred stock (Series A, B), $0.001 par value; 0 shares and 29,723,540 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 0 shares and 3,963,910 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $85,902 as of June 30, 2025 and December 31, 2024, respectively — 85,503 Stockholders' Equity (Deficit): Common stock, $0.001 par value; 150,000,000 shares and 58,251,629 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 9,373,433, and 2,574,767 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 9 2 Additional paid-in capital 130,579 1,103 Accumulated other comprehensive loss (13 ) — Accumulated deficit (97,648 ) (92,236 ) Total stockholders' equity (deficit) 32,927 (91,131 ) $ 43,750 $ 35,199 Expand TVARDI THERAPEUTICS Consolidated Statement of Operations (Unaudited) For the Three Months Ended June 30, 2025 2024 Operating expenses: Research and development $ 5,806 $ 6,531 General and administrative 3,063 650 Total operating expenses 8,869 7,181 Loss from operations (8,869 ) (7,181 ) Interest income 377 206 Other income, net 12,659 — Net income (loss) $ 4,167 $ (6,975 ) Net income (loss) per share attributable to common stockholders: Basic $ 0.51 $ (2.71 ) Diluted $ (1.00 ) $ (2.71 ) Weighted-average common shares outstanding: Basic 8,246,582 2,574,767 Diluted 8,455,223 2,574,767 Comprehensive income (loss): Net income (loss) $ 4,167 $ (6,975 ) Unrealized loss on short-term investments (15 ) — Comprehensive income (loss) $ 4,152 $ (6,975 ) Expand
